The Lancet Oncology

🚨Our July issue is now live: thelancet.com/issue/S1470-20… Explore articles on #gastrointestinalcancer, #prostatecancer, #WHO essential medicines, #NSCLC, #breastcancer, and cancer genomics

🔥DREAMM-7 trial updates (R/R multiple myeloma) 1⃣Sustained overall survival benefit with BVd vs DVd at 39.4 months @TheLancetOncol 👇 shorturl.at/f98Pr 2⃣Stable patient-reported quality of life over 28.2 months @TheLancetHaem 👇 shorturl.at/BYLay @dra_v_hungria

🔴Online now: HER2DX and survival outcomes in early-stage HER2-positive #breastcancer: an individual patient-level meta-analysis Authors: @prat_aleix, @stolaney1, and @G_Villacampa thelancet.com/journals/lanon…

Testicular cancer is the most common solid malignancy, accounting for 1–2% of all tumours in men of all ages. A Seminar aims to provide a comprehensive review of the current treatment approaches & future directions for management of testicular cancer: hubs.li/Q03vTH5h0

New @TheLancetOncol - Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study thelancet.com/journals/lanon… #GITwitter #OncTwitter

Online first: Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis thelancet.com/journals/lanon… @czwatling and colleagues Comment: Oral contraceptives and risk of liver cancer thelancet.com/journals/lanon…

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few…

July Editorial: Politics and pharma—hurdles in UK science ambitions 🔬In June, the UK government announced plans to boost science and technology research and development—a stand-off with the pharmaceutical industry over profits threatens these plans thelancet.com/journals/lanon…

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a phase 3 thelancet.com/journals/lanon… Authors: @alison_tree, @nickva1, & @EmmaHall71 @royalmarsden, @Accuray, @ICR_London

July Perspectives: You are her son, not her doctor, Nicholas W Eyrich describes his experience of having a loved one receive a life-threatening diagnosis bit.ly/4knc36G AND Solutions for tackling the global surgery crisis in west Africa bit.ly/4kjJuH8

🆕in July issue: Cabozantinib plus atezolizumab in metastatic #prostatecancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial thelancet.com/journals/lanon… @montypal, @neerajaiims, and colleagues

July issue: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study thelancet.com/journals/lanon…

July issue: Hormone therapy use and young-onset #breastcancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 🖱️thelancet.com/journals/lanon…

🗞️News: US FDA gives import exemptions to drugs made in banned factories, Sharmila Devi reports thelancet.com/journals/lanon…

Proud to launch The Lancet Oncology Middle East Series a powerful testament to our region’s scientific potential and capabilities. As one of the world’s most respected medical journals, The Lancet sets the standard for excellence. Through the Cancer Arabia Initiative, our…